You are here
Metastatic castration resistant prostate cancer (mCRPC)
Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival
Tait C. Moore D. Hodgson C. Brown M. Morris T. Growcott J. Malone M. Hughes A. Renehan A. Clarke N.W. Dive C.BJU International, Volume 114, Issue 6, 1 December 2014, Pages E70-E73
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Dr Cora N Sternberg, MD, Daniel Castellano, MD, Prof Gedske Daugaard, MD,The Lancet Neurology, Volume 15, Issue 11, October 2014, Pages 1263–1268
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, Yu D, Srinivas S.J Oncol Pharm Pract. 2014 Dec;20(6):417-25. Epub 2013 Nov 14.
A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer
Ramachandran Venkitaraman, David Lorente, Vedang Murthy, Karen Thomas, Lydia Parker, Ruth Ahiabor, David Dearnaley, Robert Huddart, Johann De Bono, Chris Parker
Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
Gong CL, Hay JW.J Natl Compr Canc Netw. 2014 Oct;12(10):1417-25.
An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J.Prostate Cancer Prostatic Dis. 2014 Dec;17(4):320-4. Epub 2014 Sep 2.
Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Zhou ZR, Liu SX, Zhang TS, Xia J, Li B.Asian Pac J Cancer Prev. 2014;15(3):1313-20.
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC
Prof Peter Hoskin, MD, Prof Oliver Sartor, MD, Prof Joe M O'Sullivan, et al.The Lancet Oncology, Volume 15, Issue 12, November 2014, Pages 1397–1406
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
Michael T. Schweizer, Xian C. Zhou, Hao Wang, Sunakshi Bassi, Michael A. Carducci, Mario A. Eisenberger, Emmanuel S. Antonarakis
European Urology, 4, 66, pages 646 - 652
Observations From Early Adoption of Radium 223 (Ra-223) in Heavily Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
D.R. McHaffie, H.J. Sharp, J. Symanowski, A.J. Crimaldi, J. Mahoney, E.F. Burgess, R. Nazemzadeh, M.R. Haake
International Journal of Radiation Oncology*Biology*Physics, 1, 90, page S440